INhibiting mechanoTRansduction as a novel approach for Oncology theraPY (INTROPY)

This project aims to develop a first-in-class mechanoinhibitor drug targeting stiffness-induced protein unfolding in solid tumors, with potential applications in cancer therapy and fibrosis.

Subsidie
€ 150.000
2025

Projectdetails

Introduction

Increased tissue stiffness is a hallmark of many solid tumours, driving tumour progression. This occurs through mechanotransduction, the process by which cells sense and respond to mechanical signals.

Key Protein Interaction

Our lab has identified a key interaction between two proteins, essential for mechanotransduction. This interaction is triggered by force-induced unfolding of a target protein, which occurs only in stiff tissues.

Proposed Therapeutic Approach

Hence, we propose a novel therapeutic approach that targets mechanotransduction by inhibiting the stiffness-induced unfolding of the target protein. This innovative approach has the potential to transform cancer therapy and provide new insights into the role of mechanical signals in disease progression.

Methodology

We developed a thermal shift assay to identify molecules that stabilize the target and inhibit its unfolding. High throughput screening (HTS) of approximately 5,000 molecules resulted in 4 hits with confirmed specific binding by NMR analysis.

Additional Hits

Two additional hits were identified, each through structure-based virtual screening and a peptide-based approach, with confirmed binding through NMR analysis.

Project Aims

In this project, we aim to validate these 6 hits and to provide proof-of-concept evidence of their potential for cancer therapy.

Validation Steps

  1. In Vitro Validation: First, we will validate hits in vitro and in cellular assays.
  2. Optimization: Second, we will optimize them with medicinal chemists to obtain lead molecules.
  3. In Vivo Evaluation: Third, we will evaluate resulting lead molecules in an in vivo mouse breast cancer model.

Expected Outcomes

By the end of the project, we expect our data to be sufficient to attract private investment and establish a spin-off company to pursue drug development into clinical phases. This will lead to a first-in-class mechanoinhibitor drug, with potential applications in cancer (with a focus on breast and pancreatic cancer) and other conditions characterized by mechanical stress, such as fibrosis.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-8-2025
Einddatum31-1-2027
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYApenvoerder

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Personalised Mechanobiological Models to Predict Tumour Growth and Anti-Cancer Drug Penetration

This project aims to develop a personalized cancer treatment framework by modeling stress-dependent tumor growth and drug penetration to enhance patient-specific therapy outcomes.

€ 1.499.693
ERC Advanced...

Mechanobiology of cancer progression

This project aims to develop an innovative in vivo platform to study tumor fibrosis and improve targeted cancer therapies by mimicking the fibrotic microenvironment of breast cancer.

€ 2.498.690
ERC Starting...

Mechano-modulation of tumor microenvironment with mechanotherapeutics and sonopermeation to optimize nano-immunotherapy

This project aims to enhance drug delivery and treatment efficacy in desmoplastic tumors by synergistically combining mechanotherapeutics and ultrasound sonopermeation, supported by computational modeling.

€ 1.500.000
ERC Advanced...

Engineering soft microdevices for the mechanical characterization and stimulation of microtissues

This project aims to advance mechanobiology by developing soft robotic micro-devices to study and manipulate 3D tissue responses, enhancing understanding of cell behavior and potential cancer treatments.

€ 3.475.660
ERC Advanced...

Targeted Re-engineering of the Tumor Matrix to Advance Immunotherapy

This project aims to disrupt the pro-fibrotic loop in pancreatic cancer using engineered biomimetics to enhance immune therapy efficacy by normalizing the tumor microenvironment.

€ 2.499.783

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering

The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.

€ 2.434.790